Cargando…
Cardiac amyloidosis: evolving pathogenesis, multimodal diagnostics, and principles of treatment
Amyloidosis is a protein deposition disorder in which insoluble fibril structures accumulate in the bodily tissues damaging the organ function. Cardiac amyloidosis is a severe but under-reported medical condition characterized by the accumulation of amyloid in the extracellular area of the myocardiu...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Leibniz Research Centre for Working Environment and Human Factors
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502203/ https://www.ncbi.nlm.nih.gov/pubmed/37720240 http://dx.doi.org/10.17179/excli2023-6284 |
_version_ | 1785106269063872512 |
---|---|
author | Medarametla, Gnana Deepthi Kahlon, Ripudaman Singh Mahitha, Lampimukhi Shariff, Sanobar Vakkalagadda, Naga Praneeth Chopra, Hitesh Kamal, Mohammad Amjad Patel, Neil Sethi, Yashendra Kaka, Nirja |
author_facet | Medarametla, Gnana Deepthi Kahlon, Ripudaman Singh Mahitha, Lampimukhi Shariff, Sanobar Vakkalagadda, Naga Praneeth Chopra, Hitesh Kamal, Mohammad Amjad Patel, Neil Sethi, Yashendra Kaka, Nirja |
author_sort | Medarametla, Gnana Deepthi |
collection | PubMed |
description | Amyloidosis is a protein deposition disorder in which insoluble fibril structures accumulate in the bodily tissues damaging the organ function. Cardiac amyloidosis is a severe but under-reported medical condition characterized by the accumulation of amyloid in the extracellular area of the myocardium, which results in thickening and stiffening of ventricular walls. Cardiac amyloidosis has recently gained much attention with its slowly surging incidence. With this study, we seek to comprehensively compile the pathophysiology and clinical picture of cardiac amyloidosis subtypes, extending a clinically oriented, up-to-date clinical approach to diagnosis and therapy. Cardiac amyloidosis can be caused by rare genetic mutations which may be inherited or acquired. The growing incidence can be attributed to advancements in imaging methods and other diagnostic modalities. Most occurrences of cardiac amyloidosis result from two forms of precursor protein: transthyretin [TTR] amyloid and immunoglobulin-derived light-chain amyloid. Prompt identification of cardiac amyloidosis can facilitate the implementation of evolving therapeutic interventions to enhance the outcomes. The modalities for the management of CA have evolved significantly in the last ten years. Apart from therapies for modifying disease and heart failure, a myriad of novel therapeutic approaches that target specific aspects of the disease, including gene therapies, are being researched. These aim at impeding its progression and improving clinical outcomes. See also Figure 1(Fig. 1). |
format | Online Article Text |
id | pubmed-10502203 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Leibniz Research Centre for Working Environment and Human Factors |
record_format | MEDLINE/PubMed |
spelling | pubmed-105022032023-09-16 Cardiac amyloidosis: evolving pathogenesis, multimodal diagnostics, and principles of treatment Medarametla, Gnana Deepthi Kahlon, Ripudaman Singh Mahitha, Lampimukhi Shariff, Sanobar Vakkalagadda, Naga Praneeth Chopra, Hitesh Kamal, Mohammad Amjad Patel, Neil Sethi, Yashendra Kaka, Nirja EXCLI J Review Article Amyloidosis is a protein deposition disorder in which insoluble fibril structures accumulate in the bodily tissues damaging the organ function. Cardiac amyloidosis is a severe but under-reported medical condition characterized by the accumulation of amyloid in the extracellular area of the myocardium, which results in thickening and stiffening of ventricular walls. Cardiac amyloidosis has recently gained much attention with its slowly surging incidence. With this study, we seek to comprehensively compile the pathophysiology and clinical picture of cardiac amyloidosis subtypes, extending a clinically oriented, up-to-date clinical approach to diagnosis and therapy. Cardiac amyloidosis can be caused by rare genetic mutations which may be inherited or acquired. The growing incidence can be attributed to advancements in imaging methods and other diagnostic modalities. Most occurrences of cardiac amyloidosis result from two forms of precursor protein: transthyretin [TTR] amyloid and immunoglobulin-derived light-chain amyloid. Prompt identification of cardiac amyloidosis can facilitate the implementation of evolving therapeutic interventions to enhance the outcomes. The modalities for the management of CA have evolved significantly in the last ten years. Apart from therapies for modifying disease and heart failure, a myriad of novel therapeutic approaches that target specific aspects of the disease, including gene therapies, are being researched. These aim at impeding its progression and improving clinical outcomes. See also Figure 1(Fig. 1). Leibniz Research Centre for Working Environment and Human Factors 2023-08-03 /pmc/articles/PMC10502203/ /pubmed/37720240 http://dx.doi.org/10.17179/excli2023-6284 Text en Copyright © 2023 Medarametla et al. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ) You are free to copy, distribute and transmit the work, provided the original author and source are credited. |
spellingShingle | Review Article Medarametla, Gnana Deepthi Kahlon, Ripudaman Singh Mahitha, Lampimukhi Shariff, Sanobar Vakkalagadda, Naga Praneeth Chopra, Hitesh Kamal, Mohammad Amjad Patel, Neil Sethi, Yashendra Kaka, Nirja Cardiac amyloidosis: evolving pathogenesis, multimodal diagnostics, and principles of treatment |
title | Cardiac amyloidosis: evolving pathogenesis, multimodal diagnostics, and principles of treatment |
title_full | Cardiac amyloidosis: evolving pathogenesis, multimodal diagnostics, and principles of treatment |
title_fullStr | Cardiac amyloidosis: evolving pathogenesis, multimodal diagnostics, and principles of treatment |
title_full_unstemmed | Cardiac amyloidosis: evolving pathogenesis, multimodal diagnostics, and principles of treatment |
title_short | Cardiac amyloidosis: evolving pathogenesis, multimodal diagnostics, and principles of treatment |
title_sort | cardiac amyloidosis: evolving pathogenesis, multimodal diagnostics, and principles of treatment |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502203/ https://www.ncbi.nlm.nih.gov/pubmed/37720240 http://dx.doi.org/10.17179/excli2023-6284 |
work_keys_str_mv | AT medarametlagnanadeepthi cardiacamyloidosisevolvingpathogenesismultimodaldiagnosticsandprinciplesoftreatment AT kahlonripudamansingh cardiacamyloidosisevolvingpathogenesismultimodaldiagnosticsandprinciplesoftreatment AT mahithalampimukhi cardiacamyloidosisevolvingpathogenesismultimodaldiagnosticsandprinciplesoftreatment AT shariffsanobar cardiacamyloidosisevolvingpathogenesismultimodaldiagnosticsandprinciplesoftreatment AT vakkalagaddanagapraneeth cardiacamyloidosisevolvingpathogenesismultimodaldiagnosticsandprinciplesoftreatment AT choprahitesh cardiacamyloidosisevolvingpathogenesismultimodaldiagnosticsandprinciplesoftreatment AT kamalmohammadamjad cardiacamyloidosisevolvingpathogenesismultimodaldiagnosticsandprinciplesoftreatment AT patelneil cardiacamyloidosisevolvingpathogenesismultimodaldiagnosticsandprinciplesoftreatment AT sethiyashendra cardiacamyloidosisevolvingpathogenesismultimodaldiagnosticsandprinciplesoftreatment AT kakanirja cardiacamyloidosisevolvingpathogenesismultimodaldiagnosticsandprinciplesoftreatment |